#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=5. Microparticles as an Indicator of Disease Activity
1-1	0-2	5.	_	_	_	_
1-2	3-17	Microparticles	abstract[1]	new[1]	coref	2-1[0_1]
1-3	18-20	as	abstract[1]	new[1]	_	_
1-4	21-23	an	abstract[1]|abstract[2]	new[1]|new[2]	coref	3-25[21_2]
1-5	24-33	Indicator	abstract[1]|abstract[2]	new[1]|new[2]	_	_
1-6	34-36	of	abstract[1]|abstract[2]	new[1]|new[2]	_	_
1-7	37-44	Disease	abstract[1]|abstract[2]|abstract|abstract[4]	new[1]|new[2]|new|new[4]	coref|coref	3-12|3-12[15_4]
1-8	45-53	Activity	abstract[1]|abstract[2]|abstract[4]	new[1]|new[2]|new[4]	_	_

#Text=Microparticles have been attracting increasing attention as potential indicators of eukaryotic cell activation .
2-1	54-68	Microparticles	abstract	giv	_	_
2-2	69-73	have	_	_	_	_
2-3	74-78	been	_	_	_	_
2-4	79-89	attracting	_	_	_	_
2-5	90-100	increasing	abstract[6]	new[6]	_	_
2-6	101-110	attention	abstract[6]	new[6]	_	_
2-7	111-113	as	_	_	_	_
2-8	114-123	potential	abstract[7]	new[7]	ana	3-1[0_7]
2-9	124-134	indicators	abstract[7]	new[7]	_	_
2-10	135-137	of	abstract[7]	new[7]	_	_
2-11	138-148	eukaryotic	abstract[7]|place[8]|event[9]	new[7]|new[8]|new[9]	_	_
2-12	149-153	cell	abstract[7]|place[8]|event[9]	new[7]|new[8]|new[9]	_	_
2-13	154-164	activation	abstract[7]|event[9]	new[7]|new[9]	_	_
2-14	165-166	.	_	_	_	_

#Text=They could provide valuable information on inflammatory processes in progress , disease activity , and the response to treatment as well as prognosis as a disease assessment indicator .
3-1	167-171	They	abstract	giv	_	_
3-2	172-177	could	_	_	_	_
3-3	178-185	provide	_	_	_	_
3-4	186-194	valuable	abstract[11]	new[11]	_	_
3-5	195-206	information	abstract[11]	new[11]	_	_
3-6	207-209	on	abstract[11]	new[11]	_	_
3-7	210-222	inflammatory	abstract[11]|abstract[12]	new[11]|new[12]	_	_
3-8	223-232	processes	abstract[11]|abstract[12]	new[11]|new[12]	_	_
3-9	233-235	in	abstract[11]|abstract[12]	new[11]|new[12]	_	_
3-10	236-244	progress	abstract[11]|abstract[12]|abstract	new[11]|new[12]|new	_	_
3-11	245-246	,	abstract[11]	new[11]	_	_
3-12	247-254	disease	abstract[11]|abstract|abstract[15]	new[11]|giv|giv[15]	coref|coref	3-26|4-17[28_15]
3-13	255-263	activity	abstract[11]|abstract[15]	new[11]|giv[15]	_	_
3-14	264-265	,	abstract[11]	new[11]	_	_
3-15	266-269	and	abstract[11]	new[11]	_	_
3-16	270-273	the	abstract[11]|abstract[16]	new[11]|new[16]	_	_
3-17	274-282	response	abstract[11]|abstract[16]	new[11]|new[16]	_	_
3-18	283-285	to	abstract[11]|abstract[16]	new[11]|new[16]	_	_
3-19	286-295	treatment	abstract[11]|abstract[16]|event	new[11]|new[16]|new	coref	16-6[132_0]
3-20	296-298	as	abstract[11]	new[11]	_	_
3-21	299-303	well	abstract[11]	new[11]	_	_
3-22	304-306	as	abstract[11]	new[11]	_	_
3-23	307-316	prognosis	abstract[11]|abstract[18]	new[11]|new[18]	_	_
3-24	317-319	as	abstract[11]|abstract[18]	new[11]|new[18]	_	_
3-25	320-321	a	abstract[11]|abstract[18]|abstract[21]	new[11]|new[18]|giv[21]	_	_
3-26	322-329	disease	abstract[11]|abstract[18]|abstract|abstract[20]|abstract[21]	new[11]|new[18]|giv|new[20]|giv[21]	coref	6-28
3-27	330-340	assessment	abstract[11]|abstract[18]|abstract[20]|abstract[21]	new[11]|new[18]|new[20]|giv[21]	_	_
3-28	341-350	indicator	abstract[11]|abstract[18]|abstract[21]	new[11]|new[18]|giv[21]	_	_
3-29	351-352	.	_	_	_	_

#Text=Hsu et al. demonstrated that release of MPs from platelets activated with collagen decreased considerably after the activity of kinase BTK was inhibited .
4-1	353-356	Hsu	person	new	_	_
4-2	357-359	et	_	_	_	_
4-3	360-363	al.	person	new	coref	13-11
4-4	364-376	demonstrated	_	_	_	_
4-5	377-381	that	_	_	_	_
4-6	382-389	release	event[24]	new[24]	coref	5-22[40_24]
4-7	390-392	of	event[24]	new[24]	_	_
4-8	393-396	MPs	event[24]|person	new[24]|new	coref	8-5
4-9	397-401	from	event[24]	new[24]	_	_
4-10	402-411	platelets	event[24]|animal[26]	new[24]|new[26]	_	_
4-11	412-421	activated	event[24]|animal[26]	new[24]|new[26]	_	_
4-12	422-426	with	event[24]|animal[26]	new[24]|new[26]	_	_
4-13	427-435	collagen	event[24]|animal[26]|substance	new[24]|new[26]|new	_	_
4-14	436-445	decreased	_	_	_	_
4-15	446-458	considerably	_	_	_	_
4-16	459-464	after	_	_	_	_
4-17	465-468	the	abstract[28]	giv[28]	coref	6-27[53_28]
4-18	469-477	activity	abstract[28]	giv[28]	_	_
4-19	478-480	of	abstract[28]	giv[28]	_	_
4-20	481-487	kinase	abstract[28]|substance[29]	giv[28]|new[29]	_	_
4-21	488-491	BTK	abstract[28]|substance[29]	giv[28]|new[29]	_	_
4-22	492-495	was	_	_	_	_
4-23	496-505	inhibited	_	_	_	_
4-24	506-507	.	_	_	_	_

#Text=Reduction of PMPs numbers in other studies with BTK inhibitor in platelet cultures was associated with a decrease in production and the release of inflammatory cytokines IL-6 and IL-8 .
5-1	508-517	Reduction	abstract[30]	new[30]	_	_
5-2	518-520	of	abstract[30]	new[30]	_	_
5-3	521-525	PMPs	abstract[30]|abstract|abstract[32]	new[30]|new|new[32]	coref	18-11
5-4	526-533	numbers	abstract[30]|abstract[32]	new[30]|new[32]	_	_
5-5	534-536	in	abstract[30]	new[30]	_	_
5-6	537-542	other	abstract[30]|abstract[33]	new[30]|new[33]	coref	12-13[99_33]
5-7	543-550	studies	abstract[30]|abstract[33]	new[30]|new[33]	_	_
5-8	551-555	with	abstract[30]|abstract[33]	new[30]|new[33]	_	_
5-9	556-559	BTK	abstract[30]|abstract[33]|substance|abstract[35]	new[30]|new[33]|new|new[35]	_	_
5-10	560-569	inhibitor	abstract[30]|abstract[33]|abstract[35]	new[30]|new[33]|new[35]	_	_
5-11	570-572	in	abstract[30]	new[30]	_	_
5-12	573-581	platelet	abstract[30]|animal|abstract[37]	new[30]|new|new[37]	coref	6-8
5-13	582-590	cultures	abstract[30]|abstract[37]	new[30]|new[37]	_	_
5-14	591-594	was	_	_	_	_
5-15	595-605	associated	_	_	_	_
5-16	606-610	with	_	_	_	_
5-17	611-612	a	event[38]	new[38]	coref	18-31[172_38]
5-18	613-621	decrease	event[38]	new[38]	_	_
5-19	622-624	in	event[38]	new[38]	_	_
5-20	625-635	production	event[38]|abstract	new[38]|new	coref	17-56[160_0]
5-21	636-639	and	event[38]	new[38]	_	_
5-22	640-643	the	event[38]|event[40]	new[38]|giv[40]	coref	17-53[158_40]
5-23	644-651	release	event[38]|event[40]	new[38]|giv[40]	_	_
5-24	652-654	of	event[38]|event[40]	new[38]|giv[40]	_	_
5-25	655-667	inflammatory	event[38]|event[40]|abstract[41]|abstract[42]	new[38]|giv[40]|new[41]|new[42]	_	_
5-26	668-677	cytokines	event[38]|event[40]|abstract[41]|abstract[42]	new[38]|giv[40]|new[41]|new[42]	_	_
5-27	678-682	IL-6	event[38]|event[40]|abstract[42]	new[38]|giv[40]|new[42]	_	_
5-28	683-686	and	event[38]|event[40]	new[38]|giv[40]	_	_
5-29	687-691	IL-8	event[38]|event[40]|abstract	new[38]|giv[40]|new	_	_
5-30	692-693	.	_	_	_	_

#Text=A considerable increase in the number of platelet , monocyte , and lymphocyte-derived microparticles ( CD3 , CD19 ) has been observed in RA patients with high disease activity .
6-1	694-695	A	event[44]	new[44]	_	_
6-2	696-708	considerable	event[44]	new[44]	_	_
6-3	709-717	increase	event[44]	new[44]	_	_
6-4	718-720	in	event[44]	new[44]	_	_
6-5	721-724	the	event[44]|abstract[45]	new[44]|new[45]	_	_
6-6	725-731	number	event[44]|abstract[45]	new[44]|new[45]	_	_
6-7	732-734	of	event[44]|abstract[45]	new[44]|new[45]	_	_
6-8	735-743	platelet	event[44]|abstract[45]|animal|object[48]	new[44]|new[45]|giv|new[48]	coref|coref	7-8[56_48]|8-7
6-9	744-745	,	event[44]|abstract[45]|object[48]	new[44]|new[45]|new[48]	_	_
6-10	746-754	monocyte	event[44]|abstract[45]|abstract|object[48]	new[44]|new[45]|new|new[48]	_	_
6-11	755-756	,	event[44]|abstract[45]|object[48]	new[44]|new[45]|new[48]	_	_
6-12	757-760	and	event[44]|abstract[45]|object[48]	new[44]|new[45]|new[48]	_	_
6-13	761-779	lymphocyte-derived	event[44]|abstract[45]|object[48]	new[44]|new[45]|new[48]	_	_
6-14	780-794	microparticles	event[44]|abstract[45]|object[48]	new[44]|new[45]|new[48]	_	_
6-15	795-796	(	_	_	_	_
6-16	797-800	CD3	abstract	new	_	_
6-17	801-802	,	_	_	_	_
6-18	803-807	CD19	_	_	_	_
6-19	808-809	)	_	_	_	_
6-20	810-813	has	_	_	_	_
6-21	814-818	been	_	_	_	_
6-22	819-827	observed	_	_	_	_
6-23	828-830	in	_	_	_	_
6-24	831-833	RA	organization|person[51]	new|new[51]	coref|coref	7-15|7-14[61_51]
6-25	834-842	patients	person[51]	new[51]	_	_
6-26	843-847	with	person[51]	new[51]	_	_
6-27	848-852	high	person[51]|abstract[53]	new[51]|giv[53]	coref	10-21[84_53]
6-28	853-860	disease	person[51]|abstract|abstract[53]	new[51]|giv|giv[53]	coref	10-10
6-29	861-869	activity	person[51]|abstract[53]	new[51]|giv[53]	_	_
6-30	870-871	.	_	_	_	_

#Text=Rodrigez-Cario et al. examined the amount of circulating microparticles and their origin in 114 RA patients .
7-1	872-886	Rodrigez-Cario	person	new	_	_
7-2	887-889	et	_	_	_	_
7-3	890-893	al.	_	_	_	_
7-4	894-902	examined	_	_	_	_
7-5	903-906	the	abstract[55]	new[55]	_	_
7-6	907-913	amount	abstract[55]	new[55]	_	_
7-7	914-916	of	abstract[55]	new[55]	_	_
7-8	917-928	circulating	abstract[55]|object[56]|object[57]	new[55]|giv[56]|giv[57]	coref|ana	7-8[57_56]|7-11[0_57]
7-9	929-943	microparticles	abstract[55]|object[56]|object[57]	new[55]|giv[56]|giv[57]	_	_
7-10	944-947	and	abstract[55]|object[57]	new[55]|giv[57]	_	_
7-11	948-953	their	abstract[55]|object[57]|object|abstract[59]	new[55]|giv[57]|giv|new[59]	_	_
7-12	954-960	origin	abstract[55]|object[57]|abstract[59]	new[55]|giv[57]|new[59]	_	_
7-13	961-963	in	_	_	_	_
7-14	964-967	114	person[61]	giv[61]	coref	13-17[107_61]
7-15	968-970	RA	organization|person[61]	giv|giv[61]	coref	9-14
7-16	971-979	patients	person[61]	giv[61]	_	_
7-17	980-981	.	_	_	_	_

#Text=The total number of MPs in platelet poor plasma was much higher in individuals with arthritis compared to a group of healthy individuals .
8-1	982-985	The	abstract[62]	new[62]	_	_
8-2	986-991	total	abstract[62]	new[62]	_	_
8-3	992-998	number	abstract[62]	new[62]	_	_
8-4	999-1001	of	abstract[62]	new[62]	_	_
8-5	1002-1005	MPs	abstract[62]|person	new[62]|giv	coref	9-5
8-6	1006-1008	in	abstract[62]	new[62]	_	_
8-7	1009-1017	platelet	abstract[62]|animal|substance[65]	new[62]|giv|new[65]	_	_
8-8	1018-1022	poor	abstract[62]|substance[65]	new[62]|new[65]	_	_
8-9	1023-1029	plasma	abstract[62]|substance[65]	new[62]|new[65]	_	_
8-10	1030-1033	was	_	_	_	_
8-11	1034-1038	much	_	_	_	_
8-12	1039-1045	higher	_	_	_	_
8-13	1046-1048	in	_	_	_	_
8-14	1049-1060	individuals	person[66]	new[66]	coref	8-19[68_66]
8-15	1061-1065	with	person[66]	new[66]	_	_
8-16	1066-1075	arthritis	person[66]|abstract	new[66]|new	coref	16-18[137_0]
8-17	1076-1084	compared	_	_	_	_
8-18	1085-1087	to	_	_	_	_
8-19	1088-1089	a	person[68]	giv[68]	_	_
8-20	1090-1095	group	person[68]	giv[68]	_	_
8-21	1096-1098	of	person[68]	giv[68]	_	_
8-22	1099-1106	healthy	person[68]	giv[68]	_	_
8-23	1107-1118	individuals	person[68]	giv[68]	_	_
8-24	1119-1120	.	_	_	_	_

#Text=The occurrence of different MPs subtypes in this study differed considerably in the RA group and was associated with the clinical course of joint inflammation :
9-1	1121-1124	The	event[69]	new[69]	_	_
9-2	1125-1135	occurrence	event[69]	new[69]	_	_
9-3	1136-1138	of	event[69]	new[69]	_	_
9-4	1139-1148	different	event[69]|abstract[71]	new[69]|new[71]	_	_
9-5	1149-1152	MPs	event[69]|person|abstract[71]	new[69]|giv|new[71]	coref	10-16[82_0]
9-6	1153-1161	subtypes	event[69]|abstract[71]	new[69]|new[71]	_	_
9-7	1162-1164	in	event[69]	new[69]	_	_
9-8	1165-1169	this	event[69]|abstract[72]	new[69]|new[72]	coref	13-14[106_72]
9-9	1170-1175	study	event[69]|abstract[72]	new[69]|new[72]	_	_
9-10	1176-1184	differed	_	_	_	_
9-11	1185-1197	considerably	_	_	_	_
9-12	1198-1200	in	_	_	_	_
9-13	1201-1204	the	abstract[74]	new[74]	_	_
9-14	1205-1207	RA	organization|abstract[74]	giv|new[74]	coref	12-20
9-15	1208-1213	group	abstract[74]	new[74]	_	_
9-16	1214-1217	and	_	_	_	_
9-17	1218-1221	was	_	_	_	_
9-18	1222-1232	associated	_	_	_	_
9-19	1233-1237	with	_	_	_	_
9-20	1238-1241	the	abstract[75]	new[75]	_	_
9-21	1242-1250	clinical	abstract[75]	new[75]	_	_
9-22	1251-1257	course	abstract[75]	new[75]	_	_
9-23	1258-1260	of	abstract[75]	new[75]	_	_
9-24	1261-1266	joint	abstract[75]|event[76]	new[75]|new[76]	coref	17-51[0_76]
9-25	1267-1279	inflammation	abstract[75]|event[76]	new[75]|new[76]	_	_
9-26	1280-1281	:	_	_	_	_

#Text=The amount of endothelial MPs was associated with the disease duration , the amount of granulocyte MPs was associated with the disease activity as assessed by DAS28 , whereas the amount of monocyte-derived MPs was associated with the presence of the rheumatoid factor .
10-1	1282-1285	The	abstract[77]	new[77]	_	_
10-2	1286-1292	amount	abstract[77]	new[77]	_	_
10-3	1293-1295	of	abstract[77]	new[77]	_	_
10-4	1296-1307	endothelial	abstract[77]|person[78]	new[77]|new[78]	coref	10-33[87_78]
10-5	1308-1311	MPs	abstract[77]|person[78]	new[77]|new[78]	_	_
10-6	1312-1315	was	_	_	_	_
10-7	1316-1326	associated	_	_	_	_
10-8	1327-1331	with	_	_	_	_
10-9	1332-1335	the	time[80]	new[80]	_	_
10-10	1336-1343	disease	abstract|time[80]	giv|new[80]	coref	10-22
10-11	1344-1352	duration	time[80]	new[80]	_	_
10-12	1353-1354	,	_	_	_	_
10-13	1355-1358	the	abstract[81]	new[81]	_	_
10-14	1359-1365	amount	abstract[81]	new[81]	_	_
10-15	1366-1368	of	abstract[81]	new[81]	_	_
10-16	1369-1380	granulocyte	abstract[81]|person[82]	new[81]|giv[82]	coref	15-15[124_82]
10-17	1381-1384	MPs	abstract[81]|person[82]	new[81]|giv[82]	_	_
10-18	1385-1388	was	_	_	_	_
10-19	1389-1399	associated	_	_	_	_
10-20	1400-1404	with	_	_	_	_
10-21	1405-1408	the	abstract[84]	giv[84]	coref	12-20[102_84]
10-22	1409-1416	disease	abstract|abstract[84]	giv|giv[84]	coref	14-2
10-23	1417-1425	activity	abstract[84]	giv[84]	_	_
10-24	1426-1428	as	abstract[84]	giv[84]	_	_
10-25	1429-1437	assessed	abstract[84]	giv[84]	_	_
10-26	1438-1440	by	abstract[84]	giv[84]	_	_
10-27	1441-1446	DAS28	abstract[84]|abstract	giv[84]|new	coref	14-19
10-28	1447-1448	,	_	_	_	_
10-29	1449-1456	whereas	_	_	_	_
10-30	1457-1460	the	abstract[86]	new[86]	_	_
10-31	1461-1467	amount	abstract[86]	new[86]	_	_
10-32	1468-1470	of	abstract[86]	new[86]	_	_
10-33	1471-1487	monocyte-derived	abstract[86]|person[87]	new[86]|giv[87]	coref	11-4[0_87]
10-34	1488-1491	MPs	abstract[86]|person[87]	new[86]|giv[87]	_	_
10-35	1492-1495	was	_	_	_	_
10-36	1496-1506	associated	_	_	_	_
10-37	1507-1511	with	_	_	_	_
10-38	1512-1515	the	abstract[88]	new[88]	_	_
10-39	1516-1524	presence	abstract[88]	new[88]	_	_
10-40	1525-1527	of	abstract[88]	new[88]	_	_
10-41	1528-1531	the	abstract[88]|abstract[90]	new[88]|new[90]	_	_
10-42	1532-1542	rheumatoid	abstract[88]|abstract|abstract[90]	new[88]|new|new[90]	coref	16-18
10-43	1543-1549	factor	abstract[88]|abstract[90]	new[88]|new[90]	_	_
10-44	1550-1551	.	_	_	_	_

#Text=The amount of MPs was also associated with the presence of traditional cardiovascular risk factors .
11-1	1552-1555	The	abstract[91]	new[91]	_	_
11-2	1556-1562	amount	abstract[91]	new[91]	_	_
11-3	1563-1565	of	abstract[91]	new[91]	_	_
11-4	1566-1569	MPs	abstract[91]|person	new[91]|giv	coref	17-53
11-5	1570-1573	was	_	_	_	_
11-6	1574-1578	also	_	_	_	_
11-7	1579-1589	associated	_	_	_	_
11-8	1590-1594	with	_	_	_	_
11-9	1595-1598	the	abstract[93]	new[93]	_	_
11-10	1599-1607	presence	abstract[93]	new[93]	_	_
11-11	1608-1610	of	abstract[93]	new[93]	_	_
11-12	1611-1622	traditional	abstract[93]|abstract[95]	new[93]|new[95]	_	_
11-13	1623-1637	cardiovascular	abstract[93]|abstract[94]|abstract[95]	new[93]|new[94]|new[95]	_	_
11-14	1638-1642	risk	abstract[93]|abstract[94]|abstract[95]	new[93]|new[94]|new[95]	_	_
11-15	1643-1650	factors	abstract[93]|abstract[95]	new[93]|new[95]	_	_
11-16	1651-1652	.	_	_	_	_

#Text=The findings of Cloutier et al. could indicate the possibility of using the studies of circulating mpICs to assess RA activity .
12-1	1653-1656	The	abstract[96]	new[96]	_	_
12-2	1657-1665	findings	abstract[96]	new[96]	_	_
12-3	1666-1668	of	abstract[96]	new[96]	_	_
12-4	1669-1677	Cloutier	abstract[96]|person	new[96]|new	_	_
12-5	1678-1680	et	abstract[96]	new[96]	_	_
12-6	1681-1684	al.	abstract[96]	new[96]	_	_
12-7	1685-1690	could	_	_	_	_
12-8	1691-1699	indicate	_	_	_	_
12-9	1700-1703	the	abstract[98]	new[98]	_	_
12-10	1704-1715	possibility	abstract[98]	new[98]	_	_
12-11	1716-1718	of	abstract[98]	new[98]	_	_
12-12	1719-1724	using	abstract[98]	new[98]	_	_
12-13	1725-1728	the	abstract[98]|abstract[99]	new[98]|giv[99]	_	_
12-14	1729-1736	studies	abstract[98]|abstract[99]	new[98]|giv[99]	_	_
12-15	1737-1739	of	abstract[98]|abstract[99]	new[98]|giv[99]	_	_
12-16	1740-1751	circulating	abstract[98]|abstract[99]|abstract[100]	new[98]|giv[99]|new[100]	_	_
12-17	1752-1757	mpICs	abstract[98]|abstract[99]|abstract[100]	new[98]|giv[99]|new[100]	_	_
12-18	1758-1760	to	_	_	_	_
12-19	1761-1767	assess	_	_	_	_
12-20	1768-1770	RA	organization|abstract[102]	giv|giv[102]	coref|coref	13-24|14-1[111_102]
12-21	1771-1779	activity	abstract[102]	giv[102]	_	_
12-22	1780-1781	.	_	_	_	_

#Text=However , different conclusions were presented by van Eijk et al. based on a study with 24 patients with an early form of RA .
13-1	1782-1789	However	_	_	_	_
13-2	1790-1791	,	_	_	_	_
13-3	1792-1801	different	abstract[103]	new[103]	_	_
13-4	1802-1813	conclusions	abstract[103]	new[103]	_	_
13-5	1814-1818	were	_	_	_	_
13-6	1819-1828	presented	_	_	_	_
13-7	1829-1831	by	_	_	_	_
13-8	1832-1835	van	person[104]	new[104]	_	_
13-9	1836-1840	Eijk	person[104]	new[104]	_	_
13-10	1841-1843	et	_	_	_	_
13-11	1844-1847	al.	person	giv	_	_
13-12	1848-1853	based	_	_	_	_
13-13	1854-1856	on	_	_	_	_
13-14	1857-1858	a	abstract[106]	giv[106]	_	_
13-15	1859-1864	study	abstract[106]	giv[106]	_	_
13-16	1865-1869	with	abstract[106]	giv[106]	_	_
13-17	1870-1872	24	abstract[106]|person[107]	giv[106]|giv[107]	coref	15-27[130_107]
13-18	1873-1881	patients	abstract[106]|person[107]	giv[106]|giv[107]	_	_
13-19	1882-1886	with	abstract[106]|person[107]	giv[106]|giv[107]	_	_
13-20	1887-1889	an	abstract[106]|person[107]|abstract[108]	giv[106]|giv[107]|new[108]	_	_
13-21	1890-1895	early	abstract[106]|person[107]|abstract[108]	giv[106]|giv[107]|new[108]	_	_
13-22	1896-1900	form	abstract[106]|person[107]|abstract[108]	giv[106]|giv[107]|new[108]	_	_
13-23	1901-1903	of	abstract[106]|person[107]|abstract[108]	giv[106]|giv[107]|new[108]	_	_
13-24	1904-1906	RA	abstract[106]|person[107]|abstract[108]|organization	giv[106]|giv[107]|new[108]|giv	_	_
13-25	1907-1908	.	_	_	_	_

#Text=The disease activity was assessed based on the ESR , C-reactive protein ( CRP ) level , and DAS28 score .
14-1	1909-1912	The	abstract[111]	giv[111]	_	_
14-2	1913-1920	disease	abstract|abstract[111]	giv|giv[111]	coref	18-36
14-3	1921-1929	activity	abstract[111]	giv[111]	_	_
14-4	1930-1933	was	_	_	_	_
14-5	1934-1942	assessed	_	_	_	_
14-6	1943-1948	based	_	_	_	_
14-7	1949-1951	on	_	_	_	_
14-8	1952-1955	the	abstract[116]	new[116]	coref	15-3[119_116]
14-9	1956-1959	ESR	abstract|abstract[116]	new|new[116]	coref	17-4
14-10	1960-1961	,	abstract[116]	new[116]	_	_
14-11	1962-1972	C-reactive	object|substance[114]|abstract[116]	new|new[114]|new[116]	_	_
14-12	1973-1980	protein	substance[114]|abstract[116]	new[114]|new[116]	_	_
14-13	1981-1982	(	abstract[116]	new[116]	_	_
14-14	1983-1986	CRP	abstract|abstract[116]	new|new[116]	coref	17-6
14-15	1987-1988	)	abstract[116]	new[116]	_	_
14-16	1989-1994	level	abstract[116]	new[116]	_	_
14-17	1995-1996	,	abstract[116]	new[116]	_	_
14-18	1997-2000	and	abstract[116]	new[116]	_	_
14-19	2001-2006	DAS28	abstract[116]|abstract|abstract[118]	new[116]|giv|new[118]	coref	17-9
14-20	2007-2012	score	abstract[116]|abstract[118]	new[116]|new[118]	_	_
14-21	2013-2014	.	_	_	_	_

#Text=Moreover , the level of serum amyloid-P ( SAP ) and the amount of circulating MPs and MPs presenting the C1q complement component was determined in the patients .
15-1	2015-2023	Moreover	_	_	_	_
15-2	2024-2025	,	_	_	_	_
15-3	2026-2029	the	abstract[119]	giv[119]	_	_
15-4	2030-2035	level	abstract[119]	giv[119]	_	_
15-5	2036-2038	of	abstract[119]	giv[119]	_	_
15-6	2039-2044	serum	abstract[119]|abstract|substance[121]	giv[119]|new|new[121]	_	_
15-7	2045-2054	amyloid-P	abstract[119]|substance[121]	giv[119]|new[121]	_	_
15-8	2055-2056	(	_	_	_	_
15-9	2057-2060	SAP	abstract	new	_	_
15-10	2061-2062	)	_	_	_	_
15-11	2063-2066	and	_	_	_	_
15-12	2067-2070	the	abstract[123]	new[123]	_	_
15-13	2071-2077	amount	abstract[123]	new[123]	_	_
15-14	2078-2080	of	abstract[123]	new[123]	_	_
15-15	2081-2092	circulating	abstract[123]|person[124]|person[125]	new[123]|giv[124]|giv[125]	coref|coref	15-15[125_124]|15-18[126_125]
15-16	2093-2096	MPs	abstract[123]|person[124]|person[125]	new[123]|giv[124]|giv[125]	_	_
15-17	2097-2100	and	abstract[123]|person[125]	new[123]|giv[125]	_	_
15-18	2101-2104	MPs	abstract[123]|person[125]|person[126]	new[123]|giv[125]|giv[126]	coref	17-32[150_126]
15-19	2105-2115	presenting	abstract[123]|person[125]|person[126]	new[123]|giv[125]|giv[126]	_	_
15-20	2116-2119	the	abstract[123]|person[125]|person[126]|abstract[129]	new[123]|giv[125]|giv[126]|new[129]	coref	17-34[152_129]
15-21	2120-2123	C1q	abstract[123]|person[125]|person[126]|abstract|abstract[129]	new[123]|giv[125]|giv[126]|new|new[129]	coref	17-36
15-22	2124-2134	complement	abstract[123]|person[125]|person[126]|object|abstract[129]	new[123]|giv[125]|giv[126]|new|new[129]	_	_
15-23	2135-2144	component	abstract[123]|person[125]|person[126]|abstract[129]	new[123]|giv[125]|giv[126]|new[129]	_	_
15-24	2145-2148	was	_	_	_	_
15-25	2149-2159	determined	_	_	_	_
15-26	2160-2162	in	_	_	_	_
15-27	2163-2166	the	person[130]	giv[130]	coref	16-1[131_130]
15-28	2167-2175	patients	person[130]	giv[130]	_	_
15-29	2176-2177	.	_	_	_	_

#Text=Nine patients were reassessed after an eight-week intensive treatment according to the COBRA ( COmBination therapy in Rheumatoid Arthritis ) regimen , which included a combined treatment with methotrexate , sulfasalazine , and prednisolone .
16-1	2178-2182	Nine	person[131]	giv[131]	_	_
16-2	2183-2191	patients	person[131]	giv[131]	_	_
16-3	2192-2196	were	_	_	_	_
16-4	2197-2207	reassessed	_	_	_	_
16-5	2208-2213	after	_	_	_	_
16-6	2214-2216	an	event[132]	giv[132]	coref	16-25[139_132]
16-7	2217-2227	eight-week	event[132]	giv[132]	_	_
16-8	2228-2237	intensive	event[132]	giv[132]	_	_
16-9	2238-2247	treatment	event[132]	giv[132]	_	_
16-10	2248-2257	according	event[132]	giv[132]	_	_
16-11	2258-2260	to	event[132]	giv[132]	_	_
16-12	2261-2264	the	event[132]|abstract[138]	giv[132]|new[138]	_	_
16-13	2265-2270	COBRA	event[132]|organization|abstract[138]	giv[132]|new|new[138]	_	_
16-14	2271-2272	(	event[132]|abstract[138]	giv[132]|new[138]	_	_
16-15	2273-2284	COmBination	event[132]|abstract|abstract[135]|abstract[138]	giv[132]|new|new[135]|new[138]	_	_
16-16	2285-2292	therapy	event[132]|abstract[135]|abstract[138]	giv[132]|new[135]|new[138]	_	_
16-17	2293-2295	in	event[132]|abstract[135]|abstract[138]	giv[132]|new[135]|new[138]	_	_
16-18	2296-2306	Rheumatoid	event[132]|abstract[135]|abstract|abstract[137]|abstract[138]	giv[132]|new[135]|giv|giv[137]|new[138]	coref	18-20[169_137]
16-19	2307-2316	Arthritis	event[132]|abstract[135]|abstract[137]|abstract[138]	giv[132]|new[135]|giv[137]|new[138]	_	_
16-20	2317-2318	)	event[132]|abstract[138]	giv[132]|new[138]	_	_
16-21	2319-2326	regimen	event[132]|abstract[138]	giv[132]|new[138]	_	_
16-22	2327-2328	,	event[132]|abstract[138]	giv[132]|new[138]	_	_
16-23	2329-2334	which	event[132]|abstract[138]	giv[132]|new[138]	_	_
16-24	2335-2343	included	event[132]|abstract[138]	giv[132]|new[138]	_	_
16-25	2344-2345	a	event[132]|abstract[138]|event[139]	giv[132]|new[138]|giv[139]	coref	17-15[146_139]
16-26	2346-2354	combined	event[132]|abstract[138]|event[139]	giv[132]|new[138]|giv[139]	_	_
16-27	2355-2364	treatment	event[132]|abstract[138]|event[139]	giv[132]|new[138]|giv[139]	_	_
16-28	2365-2369	with	event[132]|abstract[138]|event[139]	giv[132]|new[138]|giv[139]	_	_
16-29	2370-2382	methotrexate	event[132]|abstract[138]|event[139]|substance	giv[132]|new[138]|giv[139]|new	_	_
16-30	2383-2384	,	event[132]|abstract[138]|event[139]	giv[132]|new[138]|giv[139]	_	_
16-31	2385-2398	sulfasalazine	event[132]|abstract[138]|event[139]|substance	giv[132]|new[138]|giv[139]|new	_	_
16-32	2399-2400	,	event[132]|abstract[138]|event[139]	giv[132]|new[138]|giv[139]	_	_
16-33	2401-2404	and	event[132]|abstract[138]|event[139]	giv[132]|new[138]|giv[139]	_	_
16-34	2405-2417	prednisolone	event[132]|abstract[138]|event[139]|substance	giv[132]|new[138]|giv[139]|new	_	_
16-35	2418-2419	.	_	_	_	_

#Text=As expected , ESR , CRP , and DAS28 improved as a result of the treatment ; however , contrary to expectations , neither the amount of circulating MPs , nor MPs with the attached C1q component decreased , which suggests the absence of any connection between the activity of inflammation and MPs release and mpIC production .
17-1	2420-2422	As	_	_	_	_
17-2	2423-2431	expected	_	_	_	_
17-3	2432-2433	,	_	_	_	_
17-4	2434-2437	ESR	abstract	giv	_	_
17-5	2438-2439	,	_	_	_	_
17-6	2440-2443	CRP	abstract	giv	_	_
17-7	2444-2445	,	_	_	_	_
17-8	2446-2449	and	_	_	_	_
17-9	2450-2455	DAS28	abstract	giv	_	_
17-10	2456-2464	improved	_	_	_	_
17-11	2465-2467	as	_	_	_	_
17-12	2468-2469	a	_	_	_	_
17-13	2470-2476	result	_	_	_	_
17-14	2477-2479	of	_	_	_	_
17-15	2480-2483	the	event[146]	giv[146]	_	_
17-16	2484-2493	treatment	event[146]	giv[146]	_	_
17-17	2494-2495	;	_	_	_	_
17-18	2496-2503	however	_	_	_	_
17-19	2504-2505	,	_	_	_	_
17-20	2506-2514	contrary	_	_	_	_
17-21	2515-2517	to	_	_	_	_
17-22	2518-2530	expectations	abstract	new	_	_
17-23	2531-2532	,	_	_	_	_
17-24	2533-2540	neither	_	_	_	_
17-25	2541-2544	the	abstract[148]	new[148]	_	_
17-26	2545-2551	amount	abstract[148]	new[148]	_	_
17-27	2552-2554	of	abstract[148]	new[148]	_	_
17-28	2555-2566	circulating	abstract[148]|abstract[149]	new[148]|new[149]	_	_
17-29	2567-2570	MPs	abstract[148]|abstract[149]	new[148]|new[149]	_	_
17-30	2571-2572	,	_	_	_	_
17-31	2573-2576	nor	_	_	_	_
17-32	2577-2580	MPs	person[150]	giv[150]	_	_
17-33	2581-2585	with	person[150]	giv[150]	_	_
17-34	2586-2589	the	person[150]|abstract[152]	giv[150]|giv[152]	_	_
17-35	2590-2598	attached	person[150]|abstract[152]	giv[150]|giv[152]	_	_
17-36	2599-2602	C1q	person[150]|abstract|abstract[152]	giv[150]|giv|giv[152]	_	_
17-37	2603-2612	component	person[150]|abstract[152]	giv[150]|giv[152]	_	_
17-38	2613-2622	decreased	_	_	_	_
17-39	2623-2624	,	_	_	_	_
17-40	2625-2630	which	_	_	_	_
17-41	2631-2639	suggests	_	_	_	_
17-42	2640-2643	the	abstract[153]	new[153]	_	_
17-43	2644-2651	absence	abstract[153]	new[153]	_	_
17-44	2652-2654	of	abstract[153]	new[153]	_	_
17-45	2655-2658	any	abstract[153]|abstract[154]	new[153]|new[154]	_	_
17-46	2659-2669	connection	abstract[153]|abstract[154]	new[153]|new[154]	_	_
17-47	2670-2677	between	abstract[153]|abstract[154]	new[153]|new[154]	_	_
17-48	2678-2681	the	abstract[153]|abstract[154]|abstract[155]	new[153]|new[154]|new[155]	coref	18-35[174_155]
17-49	2682-2690	activity	abstract[153]|abstract[154]|abstract[155]	new[153]|new[154]|new[155]	_	_
17-50	2691-2693	of	abstract[153]|abstract[154]|abstract[155]	new[153]|new[154]|new[155]	_	_
17-51	2694-2706	inflammation	abstract[153]|abstract[154]|abstract[155]|event	new[153]|new[154]|new[155]|giv	_	_
17-52	2707-2710	and	abstract[153]|abstract[154]|abstract[155]	new[153]|new[154]|new[155]	_	_
17-53	2711-2714	MPs	abstract[153]|abstract[154]|abstract[155]|person|event[158]	new[153]|new[154]|new[155]|giv|giv[158]	_	_
17-54	2715-2722	release	abstract[153]|abstract[154]|abstract[155]|event[158]	new[153]|new[154]|new[155]|giv[158]	_	_
17-55	2723-2726	and	abstract[153]|abstract[154]	new[153]|new[154]	_	_
17-56	2727-2731	mpIC	abstract[153]|abstract[154]|abstract|abstract[160]	new[153]|new[154]|new|giv[160]	_	_
17-57	2732-2742	production	abstract[153]|abstract[154]|abstract[160]	new[153]|new[154]|giv[160]	_	_
17-58	2743-2744	.	_	_	_	_

#Text=In a recent paper , Chen demonstrated that inhibition of PMPs formation in an animal model of CIA ( collagen-induced arthritis ) and reduction of circulating PMPs was associated with a clinical decrease in the disease activity assessed as joint swelling and stiffness .
18-1	2745-2747	In	_	_	_	_
18-2	2748-2749	a	abstract[161]	new[161]	_	_
18-3	2750-2756	recent	abstract[161]	new[161]	_	_
18-4	2757-2762	paper	abstract[161]	new[161]	_	_
18-5	2763-2764	,	_	_	_	_
18-6	2765-2769	Chen	person	new	_	_
18-7	2770-2782	demonstrated	_	_	_	_
18-8	2783-2787	that	_	_	_	_
18-9	2788-2798	inhibition	event[163]	new[163]	_	_
18-10	2799-2801	of	event[163]	new[163]	_	_
18-11	2802-2806	PMPs	event[163]|abstract|event[165]	new[163]|giv|new[165]	_	_
18-12	2807-2816	formation	event[163]|event[165]	new[163]|new[165]	_	_
18-13	2817-2819	in	event[163]	new[163]	_	_
18-14	2820-2822	an	event[163]|abstract[167]	new[163]|new[167]	_	_
18-15	2823-2829	animal	event[163]|animal|abstract[167]	new[163]|new|new[167]	_	_
18-16	2830-2835	model	event[163]|abstract[167]	new[163]|new[167]	_	_
18-17	2836-2838	of	event[163]|abstract[167]	new[163]|new[167]	_	_
18-18	2839-2842	CIA	event[163]|abstract[167]|organization	new[163]|new[167]|new	_	_
18-19	2843-2844	(	_	_	_	_
18-20	2845-2861	collagen-induced	abstract[169]	giv[169]	_	_
18-21	2862-2871	arthritis	abstract[169]	giv[169]	_	_
18-22	2872-2873	)	_	_	_	_
18-23	2874-2877	and	_	_	_	_
18-24	2878-2887	reduction	abstract[170]	new[170]	_	_
18-25	2888-2890	of	abstract[170]	new[170]	_	_
18-26	2891-2902	circulating	abstract[170]|abstract[171]	new[170]|new[171]	_	_
18-27	2903-2907	PMPs	abstract[170]|abstract[171]	new[170]|new[171]	_	_
18-28	2908-2911	was	_	_	_	_
18-29	2912-2922	associated	_	_	_	_
18-30	2923-2927	with	_	_	_	_
18-31	2928-2929	a	event[172]	giv[172]	_	_
18-32	2930-2938	clinical	event[172]	giv[172]	_	_
18-33	2939-2947	decrease	event[172]	giv[172]	_	_
18-34	2948-2950	in	event[172]	giv[172]	_	_
18-35	2951-2954	the	event[172]|abstract[174]	giv[172]|giv[174]	_	_
18-36	2955-2962	disease	event[172]|abstract|abstract[174]	giv[172]|giv|giv[174]	_	_
18-37	2963-2971	activity	event[172]|abstract[174]	giv[172]|giv[174]	_	_
18-38	2972-2980	assessed	event[172]|abstract[174]	giv[172]|giv[174]	_	_
18-39	2981-2983	as	event[172]|abstract[174]	giv[172]|giv[174]	_	_
18-40	2984-2989	joint	event[172]|abstract[174]|event[175]	giv[172]|giv[174]|new[175]	_	_
18-41	2990-2998	swelling	event[172]|abstract[174]|event[175]	giv[172]|giv[174]|new[175]	_	_
18-42	2999-3002	and	event[172]|abstract[174]	giv[172]|giv[174]	_	_
18-43	3003-3012	stiffness	event[172]|abstract[174]|abstract	giv[172]|giv[174]|new	_	_
18-44	3013-3014	.	_	_	_	_
